Description: IMV Inc is a clinical-stage immuno-oncology company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
Home Page: www.imv-inc.com
IMV Technical Analysis
130 Eileen Stubbs Avenue
Dartmouth,
NS
B3B 2C4
Canada
Phone:
902 492 1819
Officers
| Name | Title |
|---|---|
| Mr. Andrew Hall M.Sc. | CEO & Director |
| Dr. Jeremy R. Graff | Chief Scientific Officer |
| Ms. Brittany Davison C.A., CPA | Corp. Sec. & Chief Accounting Officer |
| Delphine Davan | Sr. Director of Communications & Investor Relations |
| Ms. Linda Barabe M.B.A. | Sr. VP of HR & Internal Communications |
| Dr. Marianne Stanford | VP of R&D |
| Mr. Stephan Fiset | VP of Clinical Research |
| Dr. Heather Hirsch | VP of Translational Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.868 |
| Price-to-Sales TTM: | 1303.5947 |
| IPO Date: | 2018-06-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 97 |